Akebia Therapeutics, Inc.

AKBA·NasdaqCM
Compare
0.7902−0.0109 (−1.36%)today
At close: Oct 12, 4:00 PM EDT · May be delayed up to 15 min · USD
After hours0.8000+0.0098 (+1.24%)Oct 12, 7:59 PM EDT

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close0.8011
Open0.8000
Day range0.77170.8069
52-week range0.77173.2000
Off day high−2.07%
Off 52-week high−75.31%
Volume8.87M
Avg. volume (3M)6.29M
Market cap218.97M
EPS (TTM)-0.1200
Forward P/E-2.20
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)—
Shares outstanding277.11M
Short interest—
Earnings dateAug 5, 2026
Analyst target—
Profit margin—

Against its peers

Compare in full ›
AKBA BCRX KMDA IRWD CPHI HCM
Market cap 218.97M 2.14B 452.45M 621.30M 37.39M 2.38B
P/E (TTM) — — 20.6 4.9 — 136.8
Forward P/E -2.2 8.9 13.6 2.5 — 52.8
Price/book 8.6 -4.7 1.7 -3.8 1.0 1.9
Dividend yield — — 2.10% — — —
1-year change −71.68% +30.22% +17.44% +158.11% −53.23% −8.38%
Today −1.36% −2.22% −2.97% −1.57% −0.17% −2.98%

The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.

Latest news

All AKBA news ›
MarketScreener·

Akebia Therapeutics, Inc. : Insider Transactions

Follow insider transactions on Akebia Therapeutics, Inc. in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions Akebia Therapeutics, Inc. Latest insider transactions for…

MarketScreener·

Akebia Therapeutics, Inc.: Relative Strength Chart - Stock Nasdaq

Compare Akebia Therapeutics, Inc. with the company of your choice via a Relative Strength chart. Real-time AKBA price, Nasdaq stock exchange Relative Strength Chart Akebia Therapeutics, Inc. All financial news and data tailored to specific…

MarketScreener·Negative

Akebia Therapeutics Strengthens Vafseo® Patent Portfolio

Published on 06/10/2026 at 08:00 am EDT Use the lowest dose of VAFSEO sufficient to reduce the need for red blood cell transfusions. Known hypersensitivity to VAFSEO or any of its components and uncontrolled hypertension are…

MarketScreener·Positive

Akebia Therapeutics Doses First Patient in Phase 2 Ebribafusp Trial

Akebia Therapeutics said Monday it has dosed the first patient in an open-label Phase 2 basket trial testing ebribafusp as a treatment for rare complement-mediated kidney diseases. The mid-stage... Akebia Therapeutics Doses First Patient…

From articles in the 4Search news index.

In the news

13mentions in 30 days
12with it in the headline
Positivesentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.